Tina Vilsbøll (T Vilsbøll)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 60

Top Topics

Left Ventricular

Cardiovascular Risk Factors

Top Venues

Diabetes, obesity & metabolism

European journal of endocrinology

The Journal of clinical endocrinology and metabolism

Diabetic medicine : a journal of the British Diabetic Association

This page only lists publications with an associated author ORCID identifier.

Publications

Harpreet S Bajaj, Björg Ásbjörnsdóttir, Tanvir Johanning Bari, Kamilla Begtrup, Tina Vilsbøll, Julio Rosenstock
Once-weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant-level meta-analysis of the ONWARDS 1-5 trials. Diabetes, obesity & metabolism (2024)
Linda G Mellbin, Deepak L Bhatt, Jens-Peter David, Kathrine Ekström, Mark C Petrie, Søren Rasmussen, Tina Vilsbøll
Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials. European heart journal (2024)
Linda G Mellbin, Deepak L Bhatt, Jens-Peter David, Kathrine Ekström, Mark C Petrie, Søren Rasmussen, Tina Vilsbøll
Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials. European heart journal 45 (15) (2024)
Harpreet S Bajaj, Björg Ásbjörnsdóttir, Tanvir Johanning Bari, Kamilla Begtrup, Tina Vilsbøll, Julio Rosenstock
Once-weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant-level meta-analysis of the ONWARDS 1-5 trials. Diabetes, obesity & metabolism 26 (9) (2024)
Laura Smidt Hansen, Laerke Smidt Gasbjerg, Andreas Brønden, Niels B Dalsgaard, Emilie Bahne, Signe Stensen, Pernille H Hellmann, Jens F Rehfeld, Bolette Hartmann, Nicolai J Wewer Albrechtsen, Jens Juul Holst, Tina Vilsbøll, Filip K Krag Knop
The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes: a randomized crossover trial. European journal of endocrinology (2024)
Laura Smidt Hansen, Laerke Smidt Gasbjerg, Andreas Brønden, Niels B Dalsgaard, Emilie Bahne, Signe Stensen, Pernille H Hellmann, Jens F Rehfeld, Bolette Hartmann, Nicolai J Wewer Albrechtsen, Jens Juul Holst, Tina Vilsbøll, Filip K Krag Knop
The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes: a randomized crossover trial. European journal of endocrinology 191 (2) (2024)
Per Gustav Hagelqvist, Andreas Andersen, Kaisar B Maytham, Christine Rode Andreasen, Susanne Engberg, Ulrik Pedersen-Bjergaard, Julie Lyng Forman, Pär Ingemar Johansson, Jens Lykkesfeldt, Filip K Krag Knop, Tina Vilsbøll
Hemostatic Effects of Exercise-Related Hypoglycemia in Male Persons With Type 1 Diabetes. The Journal of clinical endocrinology and metabolism (2024)
Henriette H Nerild, Hannah Gilliam-Vigh, Anne-Marie Gade Ellegaard, Julie Lyng Forman, Tina Vilsbøll, David Peick Sonne, Andreas Brønden, Filip K Krag Knop
Expression of bile acid receptors and transporters along the intestine of patients with type 2 diabetes and controls. The Journal of clinical endocrinology and metabolism (2024)
Henrik Maagensen, Sofie Hædersdal, Jesper Krogh, Torben Hansen, Filip K Krag Knop, Anne Cathrine Baun Thuesen, Tina Vilsbøll
Clinical effects of SGLT2 inhibitors in seven persons with HNF1A-MODY (MODY3). Diabetic medicine : a journal of the British Diabetic Association (2024)
Per Gustav Hagelqvist, Andreas Andersen, Kaisar B Maytham, Christine Rode Andreasen, Susanne Engberg, Tommi B Lindhardt, Jens Oscar Faber, Jens Juul Holst, Julie Lyng Forman, Ulrik Pedersen-Bjergaard, Filip K Krag Knop, Tina Vilsbøll
Exercise-related hypoglycaemia induces QTc-interval prolongation in individuals with type 1 diabetes. Diabetes, obesity & metabolism (2023)
Hannah Gilliam-Vigh, Tina Jorsal, Sophie W Nielsen, Julie Lyng Forman, Jens Pedersen, Steen Seier Poulsen, Tina Vilsbøll, Filip K Krag Knop
Expression of Secretin and its Receptor Along the Intestinal Tract in Type 2 Diabetes Patients and Healthy Controls. The Journal of clinical endocrinology and metabolism (2023)
Per G Hagelqvist, Andreas Andersen, Kaisar B Maytham, Christine R Andreasen, Susanne Engberg, Tommi B Lindhardt, Jens Faber, Jens J Holst, Julie L Forman, Ulrik Pedersen-Bjergaard, Filip K Krag Knop, Tina Vilsbøll
Exercise-Related Hypoglycemia Induces QTc-Interval Prolongation in Individuals With Type 1 Diabetes. Diabetes, obesity & metabolism (2023)
Vanita R Aroda, Umut Erhan, Peter Jelnes, Juris J Meier, Morten Tind Abildlund, Richard E Pratley, Tina Vilsbøll, Mansoor Husain
Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes. Diabetes, obesity & metabolism (2023)
Rochelle N Naylor, Kashyap Amratlal Patel, Jarno L T Kettunen, Jonna M E Männistö, Julie Støy, Jacques Beltrand, Michel Polak, null null, Tina Vilsbøll, Siri Atma W Greeley, Andrew T Hattersley, Tiinamaija Tuomi
Systematic Review of Treatment of Beta-Cell Monogenic Diabetes. medRxiv : the preprint server for health sciences (2023)
Per Gustav Hagelqvist, Andreas Andersen, Kaisar B Maytham, Christine Rode Andreasen, Susanne Engberg, Tommi B Lindhardt, Jens Oscar Faber, Jens Juul Holst, Julie Lyng Forman, Ulrik Pedersen-Bjergaard, Filip K Krag Knop, Tina Vilsbøll
Exercise-related hypoglycaemia induces QTc-interval prolongation in individuals with type 1 diabetes. Diabetes, obesity & metabolism (2023)
Jesper Hallas, Jacob Harbo Andersen, Jens Soendergaard, Reimar Wernich Thomsen, Tina Vilsbøll
Changes in the use of glucose-lowering drugs: A Danish nationwide study. Diabetes, obesity & metabolism 25 (4) (2023)
Jesper Hallas, Jacob Harbo Andersen, Jens Soendergaard, Reimar Wernich Thomsen, Tina Vilsbøll
Changes in the use of glucose-lowering drugs: A Danish nationwide study. Diabetes, obesity & metabolism 25 (4) (2023)
Signe Foghsgaard, Louise Vedtofte, Emilie S Andersen, Emilie Bahne, Camilla Andreasen, Anne L Sørensen, Julie Lyng Forman, Elisabeth Reinhardt Mathiesen, Jens A Svare, Tine D Clausen, Peter Damm, Jens Juul Holst, Filip K Krag Knop, Tina Vilsbøll
Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: A 52-week randomized controlled clinical trial. Diabetes, obesity & metabolism (2023)
Christine R Andreasen, Andreas Andersen, Per G Hagelqvist, Kaisar Maytham, Julius V Lauritsen, Susanne Engberg, Jens Faber, Ulrik Pedersen-Bjergaard, Filip K Krag Knop, Tina Vilsbøll
Sustained QTc Prolongation During Recovery from Hypoglycemia in People with Type 1 Diabetes, Independently of Recovery to Hyper- or Euglycemia. Diabetes, obesity & metabolism (2023)
Christine Rode Andreasen, Andreas Andersen, Tina Vilsbøll
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease. Diabetologia (2023)
Christine Rode Andreasen, Andreas Andersen, Per Gustav Hagelqvist, Kaisar B Maytham, Julius V Lauritsen, Susanne Engberg, Jens Faber, Ulrik Pedersen-Bjergaard, Filip K Krag Knop, Tina Vilsbøll
Sustained heart rate-corrected QT prolongation during recovery from hypoglycaemia in people with type 1 diabetes, independently of recovery to hyperglycaemia or euglycaemia. Diabetes, obesity & metabolism (2023)
Henriette H Nerild, Andreas Brønden, Ida M Gether, Pernille H Hellmann, Mille Baekdal, Matthew P Gillum, Jens S Svenningsen, Bolette Hartmann, Naveen Rathor, Hanna Angelene Kudiyanur Muniraju, Jens F Rehfeld, Jens J Holst, Tina Vilsbøll, David Peick Sonne, Filip K Krag Knop
Liraglutide changes postprandial responses of gut hormones involved in the regulation of gallbladder motility. Diabetes, obesity & metabolism (2023)
Tina Vilsbøll, Caroline Ø Lindahl, Nick F Nielsen, Christian K Tikkanen
Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes. Diabetes, obesity & metabolism (2023)
Jesper Hallas, Jacob Harbo Andersen, Jens Soendergaard, Reimar Wernich Thomsen, Tina Vilsbøll
Changes in the use of glucose-lowering drugs: A Danish nationwide study. Diabetes, obesity & metabolism 25 (4) (2023)
Per Gustav Hagelqvist, Andreas Andersen, Kaisar B Maytham, Christine Rode Andreasen, Susanne Engberg, Tommi B Lindhardt, Julie Lyng Forman, Ulrik Pedersen-Bjergaard, Filip K Krag Knop, Tina Vilsbøll
Glycaemia and cardiac arrhythmias in people with type 1 diabetes: A prospective observational study. Diabetes, obesity & metabolism (2023)
Sebastian Møller Nguyen Heimbürger, Bjørn Hoe, Chris Neumann Nielsen, Natasha Chidekel Bergmann, Kirsa Skov-Jeppesen, Bolette Hartmann, Jens Juul Holst, Flemming Dela, Julie Overgaard, Joachim Størling, Tina Vilsbøll, Thomas Fremming Dejgaard, Jesper Foged Havelund, Vladimir A Gorshkov, Frank Kjeldsen, Nils Joakim Færgeman, Martin Rønn Madsen, Mikkel Bring Christensen, Filip K Krag Knop
GIP Affects Hepatic Fat and Brown Adipose Tissue Thermogenesis but Not White Adipose Tissue Transcriptome in Type 1 Diabetes. The Journal of clinical endocrinology and metabolism 107 (12) (2022)
Sofie Hædersdal, Asger Lund, Elisabeth Nielsen-Hannerup, Henrik Maagensen, Julie L Forman, Jens J Holst, Filip K Krag Knop, Tina Vilsbøll
The glucagon receptor antagonist LY2409021 does not affect gastrointestinal-mediated glucose disposal or the incretin effect in individuals with and without type 2 diabetes. European journal of endocrinology 187 (4) (2022)
Jesper Hallas, Jacob Harbo Andersen, Jens Soendergaard, Reimar Wernich Thomsen, Tina Vilsbøll
Changes in the use of glucose-lowering drugs: A Danish nationwide study. Diabetes, obesity & metabolism (2022)
Christine R Andreasen, Andreas Andersen, Per G Hagelqvist, Julius V Lauritsen, Peter Godsk Jørgensen, Susanne Engberg, Jens Faber, Bolette Hartmann, Ulrik Pedersen-Bjergaard, Filip K Krag Knop, Tina Vilsbøll
Hypoglycaemia and rebound hyperglycaemia increase left ventricular systolic function in patients with type 1 diabetes. Diabetes, obesity & metabolism 24 (10) (2022)
Signe Stensen, Liva L Krogh, Alexander H Sparre-Ulrich, Flemming Dela, Bolette Hartmann, Tina Vilsbøll, Jens Juul Holst, Mette Marie Rosenkilde, Mikkel Bring Christensen, Laerke Smidt Gasbjerg, Filip K Krag Knop
Acute concomitant glucose-dependent insulinotropic polypeptide receptor antagonism during glucagon-like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity. Diabetes, obesity & metabolism 24 (9) (2022)
Andreas Andersen, Peter Godsk Jørgensen, Jonatan I Bagger, Maria Pompea Antonia Baldassarre, Mikkel B Christensen, Ulrik Pedersen-Bjergaard, Tommi B Lindhardt, Gunnar Gislason, Filip K Krag Knop, Tina Vilsbøll
Acute changes in plasma glucose increases left ventricular systolic function in insulin-treated patients with type 2 diabetes and controls. Diabetes, obesity & metabolism 24 (6) (2022)
Jesper Hallas, Jacob Harbo Andersen, Jens Soendergaard, Reimar Wernich Thomsen, Tina Vilsbøll
Changes in the use of glucose-lowering drugs: A Danish nationwide study. Diabetes, obesity & metabolism (2022)
Susanne Grøn Nielsen, Julie Hagstrøm Danielsen, Helle Nergaard Grønbæk, Stig Molsted, Sandra Schade Jacobsen, Tina Vilsbøll, Annemarie Reinhardt Varming
Transforming Motivation for Exercise in a Safe and Kind Environment-A Qualitative Study of Experiences among Individuals with Type 2 Diabetes. International journal of environmental research and public health 19 (10) (2022)
Nicklas Järvelä Johansen, Thomas Fremming Dejgaard, Asger Lund, Camilla Schlüntz, Bolette Hartmann, Jens J Holst, Tina Vilsbøll, Henrik U Andersen, Filip K Krag Knop
Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes. Diabetes, obesity & metabolism (2021)
Christine Rode Andreasen, Andreas Andersen, Filip K Krag Knop, Tina Vilsbøll
Understanding the place for GLP-1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection. Diabetes, obesity & metabolism (2021)
Simone Theilade, Mikkel Bring Christensen, Tina Vilsbøll, Filip K Krag Knop
An overview of obesity mechanisms in humans: Endocrine regulation of food intake, eating behaviour and common determinants of body weight. Diabetes, obesity & metabolism (2021)
Katrine Bagge Hansen, Mathilde Svendstrup, Asger Lund, Filip K Knop, Tina Vilsbøll, Henrik Vestergaard
Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinic. Diabetic medicine : a journal of the British Diabetic Association 38 (10) (2021)
Sebastian Møller Nguyen Heimbürger, Bjørn Hoe, Chris N Nielsen, Natasha Chidekel Bergmann, Bolette Hartmann, Jens Juul Holst, Tina Vilsbøll, Thomas Fremming Dejgaard, Mikkel Bring Christensen, Filip K Krag Knop
The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial. Diabetologia 64 (11) (2021)
Amelie Decock, Dr Charlotte Verroken, Frederique Van de Velde, Tina Vilsbøll, Jens Juul Holst, Guy T'Sjoen, Bruno Lapauw
In patients with controlled acromegaly, indices of glucose homeostasis correlate with IGF-1 levels rather than with type of treatment. Clinical endocrinology 95 (1) (2021)
Signe Stensen, Laerke Smidt Gasbjerg, Liva S L Krogh, Kirsa Skov-Jeppesen, Alexander H Sparre-Ulrich, Mette H Jensen, Flemming Dela, Bolette Hartmann, Tina Vilsbøll, Jens Juul Holst, Mette Marie Rosenkilde, Mikkel Bring Christensen, Filip K Krag Knop
Effects of endogenous GIP in patients with type 2 diabetes. European journal of endocrinology 185 (1) (2021)
Andreas Andersen, Jonatan I Bagger, Samuel K Sørensen, Maria P A Baldassarre, Ulrik Pedersen-Bjergaard, Julie L Forman, Gunnar Gislason, Tommi B Lindhardt, Filip K Knop, Tina Vilsbøll
Associations of hypoglycemia, glycemic variability and risk of cardiac arrhythmias in insulin-treated patients with type 2 diabetes: a prospective, observational study. Cardiovascular diabetology 20 (1) (2021)
Alexander S Christensen, Sofie Hædersdal, Julie Støy, Heidi Storgaard, Ulla Kampmann, Julie L Forman, Marta Seghieri, Jens Juul Holst, Torben Hansen, Filip K Krag Knop, Tina Vilsbøll
Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA). Diabetes care 43 (9) (2020)
Mansoor Husain, Stephen C Bain, Ole K Jeppesen, Ildiko Lingvay, Rasmus Sørrig, Marianne B Treppendahl, Tina Vilsbøll
Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes, obesity & metabolism 22 (3) (2020)
Mikkel Bring Christensen, Asger B Lund, Niklas R Jørgensen, Jens Juul Holst, Tina Vilsbøll, Filip K Krag Knop
Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes. Journal of the Endocrine Society 4 (9) (2020)
Tina Vilsbøll, Ella Ekholm, Eva Johnsson, Ricardo Garcia-Sanchez, Nalina Dronamraju, Serge A Jabbour, Marcus Lind
Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial. Diabetes, obesity & metabolism 22 (6) (2020)
Esteban Jódar, Marie Michelsen, William Polonsky, Rosangela Réa, Anna Sandberg, Tina Vilsbøll, Mark L Warren, Signe Harring, Uwe Ziegler, Stephen C Bain
Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6). Diabetes, obesity & metabolism 22 (8) (2020)
Louise Vedtofte, Emilie Bahne, Signe Foghsgaard, Jonatan I Bagger, Camilla Andreasen, Charlotte Strandberg, Peter M Gørtz, Jens Juul Holst, Henning Grønbæk, Jens A Svare, Tine D Clausen, Elisabeth R Mathiesen, Nis Peter Damm, Lise L Gluud, Filip K Krag Knop, Tina Vilsbøll
One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. Journal of clinical medicine 9 (10) (2020)
Alexander S Christensen, Sofie Hædersdal, Heidi Storgaard, Kathrine Rose, Nina L Hansen, Jens Juul Holst, Torben Hansen, Filip K Krag Knop, Tina Vilsbøll
GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1α Mutation Carriers. Diabetes 69 (9) (2020)
Stewart B Harris, Martin J Abrahamson, Antonio Ceriello, Guillaume Charpentier, Marc Evans, Roger Lehmann, Andreas Liebl, Sultan Linjawi, Richard Ian Gregory Holt, Nóra Hosszúfalusi, Guy E H M Rutten, Tina Vilsbøll
Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes. Drugs 80 (2) (2020)
Sofie Hædersdal, Asger Lund, Elisabeth Nielsen-Hannerup, Henrik Maagensen, Gerrit van Hall, Jens Juul Holst, Filip K Krag Knop, Tina Vilsbøll
The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition. Diabetes 69 (12) (2020)
Marco Møller, Simon Fredholm, Mathias E Jensen, Gitta Wörtwein, Julie R Larsen, Tina Vilsbøll, Niels Odum, Anders Fink-Jensen
Proinflammatory biomarkers are associated with prediabetes in patients with schizophrenia. CNS spectrums (2020)
Tina Vilsbøll, Thomas C Blevins, Esteban Jodar, Neil Poulter, Nikolaos Tentolouris, Bue F Ross Agner, Lucine Lehmann, Lawrence Alan Leiter
Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin. Diabetes, obesity & metabolism 21 (6) (2019)
Andreas Andersen, Asger Lund, Filip K Krag Knop, Tina Vilsbøll
Glucagon-like peptide 1 in health and disease. Nature reviews. Endocrinology 14 (7) (2019)
Tina Vilsbøll, Ella Ekholm, Eva Johnsson, Nalina Dronamraju, Serge A Jabbour, Marcus Lind
Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial. Diabetes care 42 (8) (2019)
Emilie S Andersen, Asger Lund, Jonatan I Bagger, Camilla Andreasen, Magnus F Grøndahl, Carolyn F Deacon, Bolette Hartmann, Jens J Holst, Filip K Krag Knop, Tina Vilsbøll
Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes? Diabetes, obesity & metabolism 20 (8) (2018)
Maria Pompea Antonia Baldassarre, Andreas Andersen, Agostino Consoli, Filip K Krag Knop, Tina Vilsbøll
Cardiovascular biomarkers in clinical studies of type 2 diabetes. Diabetes, obesity & metabolism 20 (6) (2018)
Nikolaj Ulrik Friis, N Hoffmann, M Gyldenløve, Lone Skov, Tina Vilsbøll, Filip K Krag Knop, Heidi Storgaard
Glucose metabolism in patients with psoriasis. The British journal of dermatology 180 (2) (2018)
Tina Vilsbøll, Stephen C Bain, Lawrence Alan Leiter, Ildiko Lingvay, David Matthews, Rafael Simó, Ida Carøe Helmark, Nelun Wijayasinghe, Michael Larsen
Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes, obesity & metabolism 20 (4) (2018)
Andreas Brønden, Kristian Mikkelsen, David P Sonne, Morten Hansen, Christoffer Våben, Maria N Gabe, Mette Rosenkilde, Valentina Tremaroli, Hao Wu, Fredrik Bäckhed, Jens F Rehfeld, Jens J Holst, Tina Vilsbøll, Filip K Krag Knop
Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer. Diabetes, obesity & metabolism 20 (7) (2018)
Niels B Dalsgaard, Tina Vilsbøll, Filip K Krag Knop
Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons. Diabetes, obesity & metabolism 20 (3) (2017)